Joe G N Garcia

US Patent:

20060194765, Aug 31, 2006

Filed:

Oct 31, 2005

Appl. No.:

11/264370

Inventors:

Joe Garcia - Chicago IL, US
Konstantin Birukov - Chicago IL, US
Norbert Leitinger - Charlottesville VA, US
Valery Bochkov - Vienna, AT

International Classification:

A61K 31/685

US Classification:

514078000

Abstract:

The instant invention provides compositions, e.g., compositions comprising oxidized phospholipids, for the treatment of diseases, disorders and conditions, e.g., cute lung injury syndromes, sepsis, vascular leakage, edema, acute respiratory distress syndrome (ARDS) or acute inflammation.

US Patent:

20060258696, Nov 16, 2006

Filed:

Apr 17, 2006

Appl. No.:

11/379010

Inventors:

Jonathan Moss - Chicago IL, US
Mark Lingen - Oak Park IL, US
Patrick Singleton - Chicago IL, US
Joe Garcia - Chicago IL, US

International Classification:

A61K 31/485

US Classification:

514283000

Abstract:

The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

US Patent:

20080194611, Aug 14, 2008

Filed:

May 6, 2006

Appl. No.:

11/914984

Inventors:

John C. Alverdy - Glenview IL, US
Jonathan Moss - Chicago IL, US
Mark W. Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

International Classification:

A61K 31/485
A61K 31/445
A61P 31/00
A61P 17/00

US Classification:

514282, 514331

Abstract:

The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders. The diseases or disorders may amenable to the methods include inflammation, such as acute lung injury, atherosclerosis, gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly (pig-bel), -mediated opthalmologic infection, -mediated otologic infection and -mediated cutaneous infection. More generally, epithelial cell barrier disorders are contemplated as amenable to the prophylactic and therapeutic methods. The diseases and disorders may be induced by microbial pathogens, including bacterial pathogens such as . The invention further provides prophylactic and therapeutic methods for inhibiting the expression of bacterial PA-I lectin/adhesin and for inhibiting bacterial MvfR activity levels. Also provided is a method of using a μ-opioid receptor antagonist in the manufacture of a medicament for use in the methods described herein.

US Patent:

20080274119, Nov 6, 2008

Filed:

Mar 7, 2006

Appl. No.:

11/908058

Inventors:

Jonathan Moss - Chicago IL, US
Mark Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

Assignee:

THE UNIVERSITY OF CHICAGO - Chicago IL

International Classification:

A61K 39/395
C12N 5/06
A61K 31/439
A61P 35/00
A61P 3/10

US Classification:

4241451, 435375

Abstract:

The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

US Patent:

20090186949, Jul 23, 2009

Filed:

Feb 28, 2007

Appl. No.:

12/281102

Inventors:

John C. Alverdy - Glenview IL, US
Joe G.N. Garcia - Chicago IL, US
Steven Dudek - Frankfort IL, US

Assignee:

THE UNIVERSITY OF CHICAGO - Chicago IL

International Classification:

A61K 31/08
A61P 11/00

US Classification:

514723

Abstract:

The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound bacterial signaling compounds produced by cells of a host containing a microbial pathogen. Methods for preventing and treating cell disorders, such as epithelial cell disorders including gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly, -mediated opthalmologic infection, -mediated otologic infection and -mediated cutaneous infection, using the modulators are contemplated, as are methods for ameliorating a symptom associated with such a disorder. The invention further provides methods of treating or preventing disorders of the lung, including disorders affecting endothelial or epithelial cell barrier function, such as acute respiratory distress syndrome or pulmonary edema, as well as methods of preventing such disorders, and the above-named disorders, such as neonatal necrotizing enterocolitis, by administering a high molecular weight polyethylene glycol-like compound. Related methods of ameliorating a symptom associated with one of these disorders is also contemplated.

US Patent:

20090197922, Aug 6, 2009

Filed:

Jan 24, 2007

Appl. No.:

12/161400

Inventors:

Mardi Gomberg Maitland - Chicago IL, US
Mark J. Ratain - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US
Michael Maitland - Chicago IL, US

Assignee:

The University of Chicago - IChicago IL

International Classification:

A61K 31/44

US Classification:

514350

Abstract:

Compositions and methods of the invention are related to treating pulmonary hypertension using a Raf kinase inhibitor, such as sorafenib. IQ a particular aspect, pulmonary hypertension is pulmonary arterial hypertension.

US Patent:

20100249064, Sep 30, 2010

Filed:

Sep 5, 2008

Appl. No.:

12/676793

Inventors:

Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

Assignee:

University of Chicago - Chicago IL

International Classification:

A61K 31/7008
A61P 9/10
A61P 9/00

US Classification:

514 62

Abstract:

The present invention concerns methods and compositions involving hyaluronan that has been substantially purified to enrich for hyaluronan with a molecular weight above 500 kilodaltons. This hyaluronan can be used for diseases and conditions characterized or caused by increased vascular permeability or angiogenesis. The higher molecular weight hyaluronan restores vascular integrity and inhibits angiogenesis in embodiments of the invention.

US Patent:

20100286059, Nov 11, 2010

Filed:

Mar 12, 2010

Appl. No.:

12/723339

Inventors:

Jonathan Moss - Chicago IL, US
Mark Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

International Classification:

A61K 38/02
A61K 31/485
A61K 31/439
A61P 35/04
A61P 35/00
C12Q 1/02

US Classification:

514 193, 514282, 514289, 514295, 435 29

Abstract:

Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.